The already failed ChAdOx1 vaccine against the PCCH virus, developed jointly by the University of Oxford and the AstraZeneca laboratory, will be tested in children between 6 and 17 years of age to be part of a new study.
The foregoing was released through an official statement
from the University of Oxford, which states that the vaccine will be tested in
children in a new clinical trial before the end of this February.
Although the efficacy of the vaccine is in the midst of much
questioning, "This trial will assess whether children and young adults
ages 6 to 17 have a good immune response with the ChAdOx1 nCoV-19
vaccine," the university said in a release.
Post a Comment
We want to know your comments and concerns. Remember: Respect distinguishes us, education makes us different...